临床结核分枝杆菌分离株对潜在毒性较低的利奈唑胺衍生物 PNU-100480 的敏感性。
Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
机构信息
Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, Netherlands.
出版信息
Antimicrob Agents Chemother. 2011 Mar;55(3):1287-9. doi: 10.1128/AAC.01297-10. Epub 2011 Jan 3.
Abstract
Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).
摘要
采用 MGIT960 系统评估了临床分离结核分枝杆菌对 PNU-100480 和利奈唑胺的敏感性。这些分离株对异烟肼（INH）、利福平、乙胺丁醇和链霉素的敏感性各不相同。PNU-100480 的平均 MIC 比利奈唑胺低 3.2 倍。因此，PNU-100480 是一种很有前途的候选药物，可进一步开发作为治疗耐多药和广泛耐药结核病（MDR/XDR-TB）的辅助药物。
相似文献
1
Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
Antimicrob Agents Chemother. 2011 Mar;55(3):1287-9. doi: 10.1128/AAC.01297-10. Epub 2011 Jan 3.
2
[Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Mikrobiyol Bul. 2009 Apr;43(2):293-7.
3
In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China.
Jpn J Infect Dis. 2012;65(3):240-2. doi: 10.7883/yoken.65.240.
4
Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.
BMC Infect Dis. 2017 Dec 28;17(1):795. doi: 10.1186/s12879-017-2898-3.
5
Comparison of Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00165-18. Print 2018 Aug.
6
Evaluation of the BBL MGIT (Mycobacterial growth indicator tube) AST SIRE system for antimycobacterial susceptibility testing of Mycobacterium tuberculosis to 4 primary antituberculous drugs.
Arch Pathol Lab Med. 2000 Jan;124(1):82-6. doi: 10.5858/2000-124-0082-EOTBMM.
7
Molecular Screening Versus Phenotypic Susceptibility Testing of Multidrug-Resistant Mycobacterium tuberculosis Isolates for Streptomycin and Ethambutol.
Microb Drug Resist. 2018 Sep;24(7):923-931. doi: 10.1089/mdr.2017.0294. Epub 2018 Jan 16.
8
Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.
Int J Antimicrob Agents. 2014 Mar;43(3):231-5. doi: 10.1016/j.ijantimicag.2013.12.007. Epub 2013 Dec 31.
9
Evaluation of the ESP culture system II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculous drugs.
J Clin Microbiol. 1998 Oct;36(10):2940-3. doi: 10.1128/JCM.36.10.2940-2943.1998.
10
Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
Antimicrob Agents Chemother. 2013 Jun;57(6):2522-5. doi: 10.1128/AAC.02020-12. Epub 2013 Mar 18.
引用本文的文献
1
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis.
Trials. 2025 Aug 15;26(1):291. doi: 10.1186/s13063-025-08973-w.
2
ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis.
Res Sq. 2025 Mar 26:rs.3.rs-5931694. doi: 10.21203/rs.3.rs-5931694/v1.
3
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?
Pharmaceutics. 2024 Jun 17;16(6):818. doi: 10.3390/pharmaceutics16060818.
4
Targeting iron-scavenging tools: a recent update on siderophores inhibitors.
RSC Med Chem. 2023 Sep 6;14(10):1885-1913. doi: 10.1039/d3md00201b. eCollection 2023 Oct 18.
5
Antibiotics in the clinical pipeline as of December 2022.
J Antibiot (Tokyo). 2023 Aug;76(8):431-473. doi: 10.1038/s41429-023-00629-8. Epub 2023 Jun 8.
6
Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis.
Front Pharmacol. 2023 Jan 9;13:1032674. doi: 10.3389/fphar.2022.1032674. eCollection 2022.
7
Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.
Molecules. 2020 Dec 2;25(23):5685. doi: 10.3390/molecules25235685.
8
Molecule Property Analyses of Active Compounds for .
J Med Chem. 2020 Sep 10;63(17):8917-8955. doi: 10.1021/acs.jmedchem.9b02075. Epub 2020 Apr 20.
9
Antibiotics in the clinical pipeline in October 2019.
J Antibiot (Tokyo). 2020 Jun;73(6):329-364. doi: 10.1038/s41429-020-0291-8. Epub 2020 Mar 10.
10
Drug-resistance in : where we stand.
Medchemcomm. 2019 Jun 11;10(8):1342-1360. doi: 10.1039/c9md00057g. eCollection 2019 Aug 1.
本文引用的文献
1
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.
Antimicrob Agents Chemother. 2011 Feb;55(2):567-74. doi: 10.1128/AAC.01179-10. Epub 2010 Nov 15.
2
Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.
J Infect Dis. 2010 Sep 1;202(5):745-51. doi: 10.1086/655471.
3
Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
Clin Pharmacokinet. 2010 Aug;49(8):559-65. doi: 10.2165/11532080-000000000-00000.
4
Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis.
Int J Tuberc Lung Dis. 2009 Dec;13(12):1456-66.
5
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.
J Antimicrob Chemother. 2009 Nov;64(5):1119-20. doi: 10.1093/jac/dkp344. Epub 2009 Sep 10.
6
Comparative growth pattern of multi drug resistance versus susceptible isolates of Mycobacterium tuberculosis in mice lungs.
Indian J Med Res. 2009 Jul;130(1):58-62.
7
Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.
Am J Respir Crit Care Med. 2009 Aug 15;180(4):371-6. doi: 10.1164/rccm.200904-0611OC. Epub 2009 Jun 11.
8
A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.
Eur Respir J. 2009 Aug;34(2):387-93. doi: 10.1183/09031936.00009509. Epub 2009 Mar 12.
9
Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9. doi: 10.1128/AAC.01182-08. Epub 2008 Dec 15.
10
Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
Int J Antimicrob Agents. 2009 Jan;33(1):92-3. doi: 10.1016/j.ijantimicag.2008.06.014. Epub 2008 Sep 11.
Zotero 插件